Completed Digestion, Kidneys & Other Organs Cancer

iEndoscope: Colonoscopy Using Rapid Evaporative Ionization Mass Spectrometry (REIMS) for precision phenotyping of colonic adenomas and early colorectal cancer.

In plain English

AI plain-English summary

A new surgical snare will turn a standard colonoscope into a chemical sensor that can identify cancerous tissue in real time by analysing the smoke from cauterisation. Current colonoscopy relies on visual patterns and random biopsies to decide which polyps need removal, but this misses up to a quarter of dangerous lesions. The iEndoscope uses rapid evaporative ionisation mass spectrometry (REIMS) to capture the aerosol produced when a polyp is burned, then identifies its molecular signature within seconds. The team will build a clinical-grade device, test it on 73 patients, and compare its accuracy against narrow-band imaging and multispectral techniques. If the device works, it could transform how surgeons decide what to cut during a colonoscopy. Instead of removing all polyps and waiting for lab results, they would know immediately whether a growth is benign, pre-cancerous, or malignant. This would reduce unnecessary removals, lower complication rates, and speed up treatment for early colorectal cancer. The project also includes an economic analysis to determine whether the technology is cost-effective for the NHS.

View original technical description
The research plan will be delivered across five parallel work packages. WP1 Instrument development: We will perform precision manufacturing in collaboration with our partners at Waters and Medwork. i) Snare and energy deployment – We will optimised the snare design and standard operating procedures for safe and efficient deployment using ex vivo synthetic simulators. ii) Aspiration of aerosol during colonoscopy: For the efficient analysis of tissue in the presence of fluid from the colon or endoscope we will develop a Venturi air-jet pump with momentum-selective capture of particles , eliminating direct contact between the patient and the mass spectrometer. We will create a device ready for clinical feasibility testing. WP2 Data collection and feasibility testing: 1. ex vivo analysis. A mass spectral database will be created by analysing over 300 biobanked specimens collected as part of our ongoing research activities. All polyps will be sent for H+E staining by an independent histopathologist and molecular phenotyping using the Cancer Hotspot Panel v2. 2. in vivo analysis: The device will be prospectively tested in 73 patients undergoing elective colonoscopy for endoscopic mucosal resection (EMR) for high-risk polyps (>1cm) with a primary endpoint of diagnostic accuracy for detecting dysplasia in adenomas. Endoscopists will be blinded to the data, and machine performance will be benchmarked against NBI and multispectral imaging techniques. We will perform feasibility testing to assess barriers to clinical trials, safety and patient recruitment and establish the diagnostic accuracy to power a prospective trial. WP3 Competitor analysis: 1. Systematic review of competing technologies: We have previously reviewed margin detection technologies in breast cancer, and this methodology will be adapted for use with endoscopy. 2: Multispectral imaging: Fresh ex vivo polyps analysed by the iEndoscope will undergo analysis using DRS and ESS to generate a comparative diagnostic sensitivity analysis. We will develop a novel probe that incorporates both REIMS and imaging analysis using DRS, ESS and Fluorescence spectroscopy for seamless in-vivo use during the prospective phase. 3. Narrow Band Imaging: The primary outcome measure will be diagnostic accuracy for dysplasia detection in adenomas. Clinical staff will undergo training to standardise analysis. A qualitative questionnaire will be given to staff to assess machine stability and performance. WP4 Data storage, processing, analysis and interpretation. Data will be curated using an SQL database on a dedicated, secure computer. Suitable data processing workflows will be developed, and will include mass recalibration, profile alignment and peak picking and normalisation protocols. The statistical integration of the mass spectra with clinical, histological and molecular metadata will be performed using various uni- and multi-variate statistical techniques such as canonical correlation and partial least squares analyses. This approach will identify associations between metabolites and clinical and molecular variables. Bayesian approaches will also be used to update the classification probabilities as more data becomes available throughout the length of the study. Determination of tissue classes and molecular subtypes will be performed using a panel of machine learning techniques with appropriate controls for leave-one-patient-out cross-validation to prevent over-fitting of statistical models. Data visualisation tools will be created. WP5 Economic analysis and service delivery: Foundational work will be performed as follows: 1) the development of a methodological framework for this and future research on the impact of the iEndoscope and imaging technology in endoscopy, encompassing cost-effectiveness and feasibility analysis. 2) A prospective health resource utilization study to estimate the comparative economic costs of existing techniques, which will be used to establish cost-benefit

View the original record at the funder ↗

Related Research

Grants with similar aims, by meaning.

RaPIDE – RAman Probe for In-vivo Diagnostics (during oesophgeal) Endoscopy.
Diagnosing the Masses - Molecular pathology through multimodal mass spectrometry imaging - summary to follow
Real time tissue characterisation using mass spectrometry
Multispectral polarization-resolved endoscopy and vision for intraoperative imaging of tissue microstructure and function
Intraoperative detection of colorectal cancer using multispectral imaging

Original classification

Research

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.